Vistin Pharma ASA:
Stock exchange announcements

24/4/2024
Vistin Pharma ASA: First quarter 2024 financial results
16/4/2024
Vistin Pharma ASA: Invitation to Q1 2024 conference call
22/3/2024
Vistin Pharma ASA: Mandatory notification of trade
4/3/2024
Vistin Pharma ASA (VISTN) acquires minority share in CF Pharma (Hungary)
16/2/2024
Vistin Pharma ASA: Key information relating to the proposed cash dividend
16/2/2024
Vistin Pharma ASA: Fourth quarter and preliminary 2023 financial results
9/2/2024
Vistin Pharma ASA: Invitation to Q4 2023 conference call
23/1/2024
Ex dividend NOK 0.75 today
25/10/2023
Vistin Pharma ASA: New CEO appointed
25/10/2023
Vistin Pharma ASA: Third quarter 2023 financial results
18/10/2023
Vistin Pharma ASA: Invitation to Q3 2023 conference call
18/9/2023
Vistin Pharma ASA: Mandatory notification of trade
26/8/2023
Mandatory notification of trade in Vistin Pharma ASA
23/8/2023
Vistin Pharma ASA: Second quarter and first half 2023 financial results
16/8/2023
Vistin Pharma ASA: Invitation to Q2 2023 conference call
4/7/2023
Management in Vistin Pharma ASA purchases shares
4/7/2023
Vistin Pharma ASA: Results of offer to buy back shares
30/6/2023
Vistin Pharma ASA: Offer to buy back shares
14/6/2023
Vistin Pharma ASA (OSE: VISTIN): Presentation from today's Capital Markets Day
31/5/2023
Vistin Pharma ASA: Mandatory notification of trade
30/5/2023
Vistin Pharma ASA: Mandatory notification of trade
22/5/2023
Vistin Pharma ASA: Minutes from the Annual General Meeting 2023
12/5/2023
Disclosure of voting rights at AGM in Vistin Pharma ASA
11/5/2023
Vistin Pharma ASA (OSE: VISTIN): Invitation to Capital Markets Day on 14th of June at the metformin manufacturing plant in Kragerø
28/4/2023
Notice of Annual General Meeting in Vistin Pharma ASA
27/4/2023
Vistin Pharma ASA: Annual Report for 2022
27/4/2023
Vistin Pharma ASA: First quarter 2023 financial results
20/4/2023
Vistin Pharma ASA: Invitation to Q1 2023 conference call
17/2/2023
Vistin Pharma ASA: Fourth quarter and preliminary 2022 financial results
10/2/2023
Vistin Pharma ASA: Invitation to Q4 2022 conference call
9/12/2022
Vistin Pharma enters into a long-term renewable energy supply agreement with Statkraft
26/10/2022
Vistin Pharma ASA: Third quarter and YTD 2022 financial results
18/10/2022
Vistin Pharma ASA: Invitation to Q3 2022 conference call
11/10/2022
Vistin Pharma ASA: Invitation to Q2 2022 conference call
19/8/2022
Vistin Pharma ASA: Second quarter and first half 2022 financial results
19/5/2022
Vistin Pharma ASA: Minutes from the annual general meeting 2022
28/4/2022
Vistin Pharma ASA: Notice of Annual General Meeting
27/4/2022
Vistin Pharma ASA: Annual Report for 2021
27/4/2022
Vistin Pharma ASA: First quarter 2022 financial results
20/4/2022
Vistin Pharma ASA: Invitation to Q1 2022 conference call
16/2/2022
New interim CEO
8/2/2022
Vistin Pharma ASA: Invitation to Q4 2021 conference call

Vistin Pharma AS

Østensjøveien 27, NO-0661 Oslo
P.O. Box 6735 Etterstad, NO-0609 Oslo

Social

Linkedin
Copyright 2022 Vistin Pharma AS
Privacy
Designed by Skarpsinn
About UsHistoryVision and ValuePeopleCareerSales
SustainabilityBalance by VistinHealthy environmentPeople in focusClean operations
ProductsProducts and productionExpansion projectTechnologySustainabilityQuality
InvestorsReasons to investReportsCalendarCorporate governanceShare informationAnnouncements
ContactContact personsHeadquarterManufacturing siteGeneral Inquiry
About us
Sustainability
Products
Investors
Contact